Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab-Reference-Cited by-同舟云学术

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab

Published:2023-03 Issue:2 Volume:8 Page:101130
ISSN:2452-1094
Container-title:Advances in Radiation Oncology
language:en
Short-container-title:Advances in Radiation Oncology

Author:

Diamond Brett H.^ORCID,Belani Neel,Masel Rebecca,DeCarli Kathryn,DiPetrillo Thomas,Hepel Jaroslaw T.,Azzoli Christopher G.,Khurshid Humera,Abbas Abbas,Koffer Paul P.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference35 articles.

1. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Aupérin;J Clin Oncol,2010

2. Management of stage III non–small-cell lung cancer: ASCO guideline;Daly;J Clin Oncol,2022

3. Therapeutic management options for stage III non-small cell lung cancer;Yoon;World J Clin Oncol,2017

4. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;New Engl J Med,2017

5. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;New Engl J Med,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07

2. Associations Between Mean Lung Dose and Prevalence of Radiation Pneumonitis in Elderly Lung Cancer Patients;Anticancer Research;2024-04-27

3. An¹⁸F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy;Journal of Nuclear Medicine;2024-03-14

4. Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC;JTO Clinical and Research Reports;2024-03

5. Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists;Oncology;2024